Companies › Just-Evotec Biologics
2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JST-018 Combination of 3 monoclonal antibodies | – | Phase 1 | Antiviral Drug | Nov 2026 |
| JST-010 Monoclonal antibody | – | Phase 1 | Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07595458 | JST-018 | Phase 1 | Antiviral Drug | Infectious disease | Nov 2026 |
| NCT06943378 | JST-010 | Phase 1 | Pre-exposure Prophylaxis Against Pneumonic Plague in Healthy Adults | Other | Apr 2027 |
Cash and short-term investments of 397m EUR on 2024-12-31; operating cash flow positive
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.